Fax: (713) 794-4297
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS
Article first published online: 8 MAY 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 22, pages 5550–5559, 15 November 2012
How to Cite
Kadia, T. M., Kantarjian, H., Kornblau, S., Borthakur, G., Faderl, S., Freireich, E. J., Luthra, R., Garcia-Manero, G., Pierce, S., Cortes, J. and Ravandi, F. (2012), Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer, 118: 5550–5559. doi: 10.1002/cncr.27596
Fax: (713) 794-4297
- Issue published online: 30 OCT 2012
- Article first published online: 8 MAY 2012
- Manuscript Accepted: 21 FEB 2012
- Manuscript Revised: 16 FEB 2012
- Manuscript Received: 11 OCT 2011
- acute myeloid leukemia (AML);
- signal transduction;
- cytarabine (AraC)
Activating mutations in RAS are frequently present in patients with acute myeloid leukemia (AML), but their overall prognostic impact is not clear.
A retrospective analysis was performed to establish the clinical characteristics of patients with RAS-mutated (RASmut) AML, to analyze their outcome by therapy, and to describe the proteomic profile of RASmut compared with wild-type RAS (RASWT) AML.
Of 609 patients with newly diagnosed AML, 11% had RASmut. Compared with RASWT, patients with RASmut AML were younger (median age, 54 years vs 63 years; P = .001), had a higher white blood cell count (16K mm−3 vs 4K mm−3 ; P < 0.001) and bone marrow blast percentage (56% vs 42%; P = .01) at diagnosis, and were less likely to have an antecedent hematologic disorder (36% vs 50%; P = .03). The inv(16) karyotype was overrepresented in patients with RASmut and the −5 and/or −7 karyotype was underrepresented. RAS mutations were found to have no prognostic impact on overall survival or disease-free survival overall or within cytogenetic subgroups. There was a suggestion that patients with RASmut benefited from cytarabine (AraC)-based therapy. Proteomic analysis revealed simultaneous upregulation of the RAS-Raf-MAP kinase and phosphoinositide 3-kinase (PI3K) signaling pathways in patients with RASmut.
RAS mutations in AML may delineate a subset of patients who benefit from AraC-based therapy and who may be amenable to treatment with inhibitors of RAS and PI3K signaling pathways. Cancer 2012. © 2012 American Cancer Society.